Compare IMAX & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMAX | OGN |
|---|---|---|
| Founded | 1967 | 1923 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 1997 | 2020 |
| Metric | IMAX | OGN |
|---|---|---|
| Price | $40.68 | $6.63 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 4 |
| Target Price | ★ $44.44 | $11.75 |
| AVG Volume (30 Days) | 987.0K | ★ 4.1M |
| Earning Date | 06-01-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 1.19% |
| EPS Growth | ★ 31.25 | N/A |
| EPS | 0.63 | ★ 0.72 |
| Revenue | $410,212,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $9.80 | $0.42 |
| Revenue Next Year | $7.11 | $1.67 |
| P/E Ratio | $64.39 | ★ $9.35 |
| Revenue Growth | ★ 16.47 | N/A |
| 52 Week Low | $20.48 | $6.18 |
| 52 Week High | $43.16 | $15.88 |
| Indicator | IMAX | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.80 | 32.93 |
| Support Level | $35.94 | $6.34 |
| Resistance Level | $43.16 | $7.87 |
| Average True Range (ATR) | 1.68 | 0.30 |
| MACD | 0.27 | -0.10 |
| Stochastic Oscillator | 66.11 | 4.39 |
Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.